PHC Live Cell Metabolic Analyzer (LiCellMo) Receives 2024 Innovation Award from The Analytical Scientist
12.12.2024 07:00:00 CET | Business Wire | Press release
The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo, Japan; President: Nobuaki Nakamura), has received a 2024 Innovation Award from The Analytical Scientist1 for its live cell metabolic analyzer, LiCellMoTM. LiCellMo, launched for research use in Japan in September and the United States, UK, EU, China and other Asian select geographies in October2, provides continuously measured data on key cellular metabolic pathways3, giving researchers a precise picture of previously unobservable changes in the state of cells over time and allowing them to make more informed research decisions. This will help contribute to novel research findings and important advances in therapies. It is designed to reveal cellular metabolic mechanisms and improve the reproducibility and quality of cell cultures in the development of manufacturing processes for cell and gene therapy products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241211103952/en/
*For research purposes only. (Graphic: Business Wire)
The Analytical Scientist focuses on the people, technology and innovations shaping measurement science. The publication issues its annual Innovation Awards to recognize technical advances that are positioned to open doors in analytical sciences.
In research for new cell and gene therapies (CGT), it is essential to assess the state of cells and create an optimal cell culture environment. LiCellMo allows researchers to visualize metabolic changes in cell cultures in real time, providing a more complete picture of cell activity for research uses in CGT. Instead of requiring researchers to take periodic samples of the culture medium for evaluating cell metabolism, which can make it difficult to monitor changes in cell conditions over time and carries the risk of contamination, LiCellMo provides minute-by-minute measurements of glucose and lactate levels in the culture medium. LiCellMo can be easily installed in a laboratory’s existing compatible CO2 incubator with no change to the usual culture environment. It offers researchers a flexible solution to challenges faced in conventional cell culture methods.
PHC Corporation is a subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global collection of healthcare companies referred to collectively as PHC Group. The in-line monitoring technology4 featured in LiCellMo builds on proprietary technology from a blood glucose monitoring sensor developed by another part of PHC Corporation, the In Vitro Diagnostics (IVD) Division.
Chikara Takauo, Director of PHC Corporation and Head of the Biomedical Division, said, “We believe LiCellMo will give researchers the opportunity to gain unprecedented new knowledge on cell metabolism, especially in the fields of cancer immunology and stem cell research, and advance the manufacturing process for new treatments in those fields. This award is a recognition of both the immediate contribution of LiCellMo in research laboratories and of its promise for supporting the development of future therapies.”
1theanalyticalscientist.com/techniques-tools/the-analytical-scientist-innovation-awards-2024-10
2www.phchd.com/global/phc/news/2024/0904
3 A series of biochemical reactions within cultured cells that produce the energy required for cellular functions and survival.
4 A technology that enables continuous measurement of cellular metabolites in culture medium without the need for sampling, achieved by maintaining constant immersion in the medium.
About the Biomedical Division of PHC Corporation
Established in 1969, PHC Corporation is a Japanese subsidiary of PHC Holdings Corporation (TOKYO: 6523), a global healthcare company that develops, manufactures, sells, and services solutions across diabetes management, healthcare solutions, life sciences and diagnostics. The Biomedical Division supports the life sciences industry helping researchers and healthcare providers in around 110 countries and regions through its PHCbi-branded laboratory and equipment and services including CO2 incubators and ultra-low temperature freezers.
www.phchd.com/global/phc
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TOKYO: 6523) is a global healthcare company with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Epredia, Ascensia Diabetes Care, LSI Medience Corporation, Mediford, and Wemex. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2023 were JPY 353.9 billion with global distribution of products and services in more than 125 countries.
www.phchd.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241211103952/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riskified Study Finds Consumers Aren’t Ready to Hand Over Control as AI Transforms Shopping, with Over Half Afraid of Online Fraud27.4.2026 14:00:00 CEST | Press release
New Q1 2026 “Agentic Commerce Pulse” survey from Riskified reveals a growing trust gap in agent-driven commerce, as consumers embrace AI across the shopping journey but remain hesitant to hand over control amid concerns over fraud, security, and accountability Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released the Q1 2026 edition of its Agentic Commerce Pulse, a quarterly research series tracking agentic commerce risks and consumer engagement. Following Riskified’s inaugural Q4 2025 survey, which first highlighted the rapid emergence of agent-driven commerce, the latest findings reveal a more complex reality: while AI adoption remains strong, consumer trust is not keeping pace. A widening gap is emerging between how shoppers use AI and how much control they are willing to give it. The survey, conducted among consumers across the United States and the United Kingdom, shows that AI is now firmly embedded in product discovery and decision-maki
Nine in 10 Expect Cross-Border M&A Surge, But 71% of Dealmakers Have Already Changed Course on Deals27.4.2026 14:00:00 CEST | Press release
90% of dealmakers expect cross-border M&A activity to increase over the next 12–24 months75% cite foreign direct investment screening as the biggest threat to deal completion88% report longer signing-to-close timelines than three years ago Cross-border M&A is set for a strong resurgence, with nine in 10 senior dealmakers expecting activity to increase over the next 12 to 24 months, according to new research from CSC, the leading provider of business administration and compliance solutions. However, despite this renewed momentum, execution risk is rising, with regulatory scrutiny and operational challenges making it harder to get deals over the line. CSC¹ surveyed 200 director level and above global dealmakers across private equity, corporate, legal, and advisory roles who have worked on cross-border transactions in the past two years. The report, The New Reality of Cross-Border M&A: More Deals, More Friction, explores how firms are navigating an increasingly complex global deal environ
Mundipharma announces positive topline results from Phase III ReSPECT trial assessing ▼REZZAYO® (rezafungin) for the prophylaxis of invasive fungal diseases in allogeneic haematopoietic stem cell transplantation patients27.4.2026 13:43:00 CEST | Press release
For Trade and Medical Media Only The study primary endpoint was met, showing non-inferiority vs. standard antimicrobial regimen in fungal-free survival at Day 90 Study showed favourable benefit for toxicity-related discontinuations and drug-drug interactions (DDIs) Rezafungin was well tolerated, with a safety profile comparable to standard antimicrobial regimens (SARs) Mundipharma today announced positive Phase III topline results from the global ReSPECT clinical trial evaluating REZZAYO® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). The ReSPECT Phase III trial, one of the largest antifungal, multicentre, randomised, double-blind studies evaluated the efficacy and safety of once weekly rezafungin compared with a SAR for the prophylaxis of IFDs, including infections caused by Candida, Aspergillus, and Pneumocystis, in adults undergoing allogeneic HSCT. Patients undergoing a
vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 13:00:00 CEST | Press release
Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260415938477/en/ Photo credit: Jos Schmid, Photographer
tesa Selects Kinaxis as the Digital Backbone for Global Integrated Business Planning Transformation27.4.2026 13:00:00 CEST | Press release
Kinaxis Maestro™ platform to serve as the foundation for a multi‑year transformation to resilient, globally orchestrated planning ecosystem Kinaxis® (TSX: KXS), a global leader in end‑to‑end supply chain orchestration, today announced that tesa SE, a global manufacturer of adhesive tapes and self-adhesive product solutions, has selected the Kinaxis Maestro™ platform as a core enabler of its global, multi‑year supply chain and integrated business planning (IBP) transformation. Following an extensive evaluation, tesa selected Kinaxis to support its evolution from regionally fragmented planning practices toward a centrally governed, globally orchestrated IBP operatingmodel. Kinaxis will support tesa in improving enterprise-wide transparency, strengthening resilience, and enabling faster, more informed decision making across an increasingly complex and volatile global supply chain network. With 130 years of innovation, tesa is one of the world’s leading manufacturers of adhesive tapes and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom